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Aortic annulus sizing strategy in TAVI, comparison of echocardiogra-
phy and CT, impact on aortic regurgitation incidence and patients
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Background: Aortic regurgitation (AR) after TAVI is the main limitation of
this procedure. The aim of this study was to evaluate i) aortic annulus sizing by
CT and/or echocardiography (TTE or TEE) ii) the incidence of AR and its deter-
minism iii) the prognostic impact of AR and other survival predictors.
Methods: 136 consecutive patients undergoing TAVI were included
between 2010 and 2013. The aortic annulus sizing for prosthesis choice was
done by TEE in 29 patients and by CT in 107 patients. Aortic valve calcium
volume was measured by the volume technique in 67% of patients who have
got CT. Follow-up was performed at 1, 6, 12 and 24 months.
Results: Aortic annulus sizing by TTE and TEE echocardiography (TEE)
were well correlated (r=0,73, p=0,0001, n=51) but were significantly lower
than CT sizing (p < 0,0001). The incidence of AR ≥ 2/4 was 13% and was not
significantly different according to the strategy of aortic annulus sizing for
prosthesis choice. No predictor of AR≥ 2/4 was identified. Calcium volume
was not associated either with AR with 1 month mortality. Mortality was 13%
at 1 month, 25% at 1 year and 39% at 2 years. Predictors of mortality at
2years in univariate analysis were Euroscore> 25%, aortic regurgitation ≥ 2/4,
renal failure with creatinin> 130μmol/l, anemia after TAVI < 8g/dl, trans
aortic gradient before TAVI < 30mmHg and tamponade. In multivariate anal-
ysis, independent predictors were aortic regurgitation ≥ 2/4, anemia after
TAVI < 8g/dl and tamponade (OR 2,75 CI 1,3-6,7; OR 2,5 CI 1,1-5,75 et OR
4,5 CI 1,30-15,55 respectively).
Conclusion: This study showed that aortic annulus sizing by echocardiog-
raphy is significantly lower than sizing by CT. AR have an independent prog-
nostic on survival. Prevention of aortic regurgitation is an important issue for
the future of this technique.
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Introduction: The PARTNER trial has shown that TAVI is not inferior to
surgical aortic valve replacement (AVR) in high-risk aortic stenosis. However,
real life registry comparing TAVI and surgery are lacking.
Methods: monocentric registry of high-risk patients (lEUROSCORE1
≥15%) undergoing TAVI (114 patients) or AVR (81 patients) between 2009
and 2013 in our institution.
Results: mean age was 84,4 and 83,6 yo (p=NS). TAVI patients had higher
EUROSCORE1 (31 vs 24.5%, p<0,001), lower LVEF (48,4 vs 57%, p<0,0001)
and lower mean aortic gradient (46 vs 53mmHg, p=0,0001). Mortality in-hospital
was not statistically different between TAVI and AVR; 9,6 vs 17,3% respectively
(p=0,12). TAVI patients presented more vascular complications (11,4 vs 0%,
p= 0,001), needed more Pace-Maker (24,6 vs 4,9%, p<0,0001) but presented less
in-hospital infections (11 vs 19%, p=0,008), less new atrial fibrillation (20 vs 41%,
p=0,002), and needed less transfusions (25,4 vs 80,2%, p<0,0001). 
Conclusion:  the present registry results confirm that TAVI is a real alter-
native to surgery in patients with at high surgical risk. Longer follow up is
required to confirm these results.
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TAVI for paradoxical or not low-flow low- gradient aortic stenosis
patients: is it always a safe and useful procedure?
Nicolas Debry, Arnaud Sudre, Cédric Delhaye, Mohamad Koussa,
Thomas Modine
CHRU Lille, Lille, France
The aim of the study was to assess the prognosis of three different aortic
stenosis populations operated by TAVI: Severe aortic stenosis (SAS), low-
flow low-gradient aortic stenosis (LFLG) and paradoxical low-flow low-gra-
dient aortic stenosis (PLFLG).
Between January 2010 and August 2013, patients with severe symptomatic
aortic stenosis were consecutively referred to our institution, for TAVI because of
multiple comorbidities and excessive surgical risk. We defined and split patients
into 3 populations as followed: PLFLG (iAVA≤0.6 cm2, MG≤40 mmHg,
SVI≤35mL/m2, LVEF≥50%, Zva>4.5 mmHg/mL/m2, MaxV<4m/s), LFLG
(iAVA≤0.6 cm2, MG≤40 mmHg, MaxV<4m/s, LVEF≤50%, SVI≤3 5mL/m2), and
SAS (MaxV>4 m/s, MG>40 mmHg, LVEF>50%). The primary endpoint of our
study was to evaluate global and cardiovascular mortalities; secondary endpoints
included VARC 2 variables. A significant decrease in survival rate regarding the
all-cause mortality (p=0.02) and cardiovascular mortality (p=0.05) was observed
in the LFLG group (n=59) in comparison to the PLFLG (n=31) and SAS (n=172)
groups, which had similar survival rates. Regarding the immediate post-procedural
outcomes, the LFLG group had more CHF (p<0.001) and a higher BNP before
discharge (p=0.009) than the other groups. VARC 2 variables analysis did not
show any significant results. Intrahospital and 30-days mortalities were higher in
the PLFLG and LFLG groups (p=0.05). There was a trend toward an increase in
MACCE in the LFLG group (p=0.13) at one month. TAVI for PLFLG patients is
April 24th, Thursday 2014
AVR TAVI p
n 81 114
Age 83.6 84.4 0.21
Euroscore1 (%) 24.5 31 <0.0001
FEV (%) 57.1 48.5 <0.0001
DTVG (mm) 51 54 0.086
Mean Gradient (mmHg) 53 46 0.008
Creatinin pre (microM/L) 111 138 0.003
Hemoglobin pre (g/100) 12.6 11.6 <0.0001
Death  (%) 17.3 9.6 0.12
Vascular complication (%) 0 11.4 0.001
Infection (%) 19 11 0.008
Dialysis (%) 13.6 11.4 0.65
AFIB post (%) 41 20 0.002
Pericardial effusion (%) 2.5 8.8 0.13
Stroke (%) 4.9 1.8 0.23
Pace Maker (%) 4.9 24.6 <0.0001
Transfusions (%) 80 25 <0.0001
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feasible, safe, and has favourable outcomes. TAVI is a reasonable alternative in
this group of patients, unlike LFLG patients who present higher mortality rate.
Abstract 0049 – Figure: All-cause mortality Survival Rate
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Oversizing, undersizing or just the right sizing for TAVI patients? 
Nicolas Debry, Arnaud Sudre, Cédric Delhaye, Mohamad Koussa,
Thomas Modine
CHRU Lille, Lille, France
Oversizing strategies to avoid post-procedural aortic leak following TAVI
are developing. The purpose of the study was to investigate if the oversizing
strategy compared with normal sizing was deleterious on the immediate and
late post-procedural outcomes.
From January 2010 to August 2013, consecutive severe symptomatic aortic
stenosis patients were referred for TAVI. They all underwent preoperative Mul-
tiSlice-angio CT scan (MSCT) and the procedures were achieved using Edwards
Sapien® or Corevalve devices®. Early and late follow-up were completed. Retro-
spectively, according to pre-procedural MSCT and the valve size, patients were
classified into three continuous groups: normal sizing, moderate and severe over-
sizing; depending on the ratio between the prosthesis area and the annulus area
indexed and calculated on MSCT. Main endpoint was the all-cause and cardiovas-
cular mortality and secondary endpoints corresponded to the VARC2 endpoints. 
268 patients had a MSCT and underwent TAVI procedure, with mainly Core-
valve®. While all-cause and cardiovascular mortality rates were similar in all
groups, post-procedural new pace-maker implantation rate was significantly
higher in the severe oversizing group (p=0.03), while we observed more in-hos-
pital congestive heart-failure (p=0.02) and tamponade (p=0.02) in the normal
sizing group. There was also a trend toward more moderate to severe AR in the
normal sizing group (p=0.12). At 1 month there was significantly more MACCE
in the normal sizing group (p=0.03). Oversizing based on this ratio is a safe and
feasible strategy to reduce aortic leak with lower rates of immediate post-proce-
dural complications and a similar long-term survival.
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Immediate and long-term results of repeat percutaneous mitral valvu-
loplasty
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Khédija Mzoughi, Kais Mrabet, Fethia Ben Moussa, Sondos Kraiem
Hôpital Habib Thameur, Cardiologie, Tunis, Tunisie
Introduction:  it is unknown whether patients who developed symptom-
atic mitral restenosis after percutaneous mitral valvuloplasty (PMV) may ben-
efit from repeat PMV (re-PMV).The purpose of this study is to assess the
immediate and long-term results of the re-PMV in patients with mitral reste-
nosis following to previous PMV.
Methods: Retrospective study from a series of 40 procedures of re-PMV
with the Inoue balloon at 8±4 years after prior procedure, performed between
1996 and 2012. A clinical and ultrasound follow-up was achieved in
31 patients with a mean follow-up period of 43±26 months.
Results: The mean age of patients was 43±11 years [23; 63]. 87,5% of the
population being female (5 men and 35 women). The immediate procedural
success was achieved in 31 patients (77.5%). A severe mitral regurgitation
(MR) was observed in 3 patients (7.5%). A cerebrovascular stroke occurred in
1 patient (2.5%). No death or cardiac tamponade were noted. Class III or IV
of NYHA, a pre-procedural MR, pulmonary hypertension and a Padial score
>10 were identified as predictors of failure. More the score of Wilkins is high
(>8), more it is predictive of failure. Only a left atrial area ≤ 25 cm² was
linked to high risk of severe MR. At long-term, most patients (84%) had no
functional impairment, the mean mitral valve area was 1,5±0,33 cm² [0,9;2,2],
mitral restenosis was observed in 13 patients (42%) at 53±30 months [9;128]
after re-PMV. 9 patients had mitral valve replacement (32%), 4 patients
underwent a re-PMV (13%), 2 patients presented thromboembolic events (6%)
and no death. Only the male had been identified as a predictor of restenosis.
Conclusion: Re-PMV in patients with restenosis after a prior PMV is fea-
sible, effective and achieves interesting immediate and long-term results.
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Introduction: Observations of EDWARDS SAPIEN prosthesis (ED SA)
once deployed in vivo, shows a frequent elliptic geometry, which can cause
inadequate transvalvular hemodynamic and the occurence of valvular regurgi-
tation (intra and/or para).
Objectives: This study aims to quantify in vitro, hemodynamic and val-
vular regurgitation of ED SA in circular and elliptic deployment conditions. 
Method: A pulsed simulator reproducing the human circulation was used. ED
SA 23 and 26 were implanted in circular annulus with increasing diameter (18, 20,
22mm for the size 23 and 21, 23, 25mm for 26) and in 4 elliptic annulus for each
size prosthesis (3 annulus with increasing Eccentricity Index (EI) at 0.17, 0.26, 0.33
starting to a small fixed diameter and 1 with the smallest and biggest diameters of
circular annulus). The Effective Orifice Area (EOA) was calculated by the conti-
nuity equation and mean transvalvular gradient (TVG) were obtained by Doppler.
The performance index (PI=100x(EOA/annulus area) was calculated. The ultra-
sound allowed the research of regurgitation, quantified by flow measurement. 
Results: The highest TVG were observed for circular annulus 18 and
20mm, respectively 17.7 and 12.2mmHg, which was correlated with the
lowest EOA (1.27 and 1.44 cm2). We observed a mismatch leaflets-stent for
annulus 18 with plicature of leaflets. Hemodynamic parameters and mean PI
(48.5 vs 43.2) were better with elliptic geometry than circular. No significant
intraprosthetic regurgitation was observed. Just 1 paraprosthetic regurgitation
occured for the ED SA 26 in the elliptic annulus with largest EI. 
Conclusion: Hemodynamic parameters of ED SA obtained in vitro with
elliptic geometry appear to be better than those with circular. A "leaflets-stent
mismatch" can occur in the case of undersizing in annulus with smaller area.
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